Literature DB >> 14576771

Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2.

E Mori1, M Thomas, K Motoki, K Nakazawa, T Tahara, K Tomizuka, I Ishida, S Kataoka.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in tumor cells without toxicity to normal cells, but some recombinant versions of TRAIL caused hepatocyte death. We generated fully human monoclonal antibodies (mAbs) that bind specifically to TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2), which mediate apoptosis signal when they ligate with TRAIL, to investigate the contribution of each receptor to induce tumor cell apoptosis and hepatocyte toxicity. All of mAbs to TRAIL-R1 and TRAIL-R2 induced cell death in several cancer cell lines susceptible to TRAIL but not in human umbilical vein endothelial cells in vitro. Both anti-TRAIL-R1 mAbs and anti-TRAIL-R2mAbs also caused cell death in hepatocytes. However, a subset of mAbs to TRAIL-R2, which was characterized by the TRAIL blocking activity, did not show strong hepatocyte toxicity. These results indicate that human normal hepatocytes are susceptible to both TRAIL-R1- and TRAIL-R2-mediated apoptosis signal. Cell Death and Differentiation (2004) 11, 203-207. doi:10.1038/sj.cdd.4401331 Published online 24 October 2003

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14576771     DOI: 10.1038/sj.cdd.4401331

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  19 in total

Review 1.  Following the TRAIL from hepatitis C virus and alcohol to fatty liver.

Authors:  S C Afford; D H Adams
Journal:  Gut       Date:  2005-11       Impact factor: 23.059

2.  The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases.

Authors:  Brett D Shepard; Andrew D Badley
Journal:  Antiinfect Agents Med Chem       Date:  2009-04-01

Review 3.  The promise of TRAIL--potential and risks of a novel anticancer therapy.

Authors:  Ronald Koschny; Henning Walczak; Tom M Ganten
Journal:  J Mol Med (Berl)       Date:  2007-04-17       Impact factor: 4.599

4.  Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.

Authors:  Kazuyoshi Takeda; Yuko Kojima; Kenichi Ikejima; Kenichi Harada; Shunhei Yamashina; Kyoko Okumura; Tomonori Aoyama; Steffen Frese; Hiroko Ikeda; Nicole M Haynes; Erika Cretney; Hideo Yagita; Noriyoshi Sueyoshi; Nobuhiro Sato; Yasuni Nakanuma; Mark J Smyth; Ko Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-30       Impact factor: 11.205

Review 5.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

Review 6.  Understanding cytokine and growth factor receptor activation mechanisms.

Authors:  Mariya Atanasova; Adrian Whitty
Journal:  Crit Rev Biochem Mol Biol       Date:  2012-10-09       Impact factor: 8.250

7.  Efficient antibody production upon suppression of O mannosylation in the yeast Ogataea minuta.

Authors:  Kousuke Kuroda; Kazuo Kobayashi; Yoshinori Kitagawa; Taishiro Nakagawa; Haruhiko Tsumura; Toshihiro Komeda; Daisuke Shinmi; Eiji Mori; Kazuhiro Motoki; Kazumi Fuju; Teruyuki Sakai; Koichi Nonaka; Takeshi Suzuki; Kimihisa Ichikawa; Yasunori Chiba; Yoshifumi Jigami
Journal:  Appl Environ Microbiol       Date:  2007-11-26       Impact factor: 4.792

8.  Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.

Authors:  John B Fiveash; G Yancey Gillespie; Patsy G Oliver; Tong Zhou; Michael L Belenky; Donald J Buchsbaum
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-06-01       Impact factor: 7.038

9.  Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.

Authors:  Claire L Dobson; Sarah Main; Philip Newton; Matthieu Chodorge; Karen Cadwallader; Robin Humphreys; Vivian Albert; Tristan J Vaughan; Ralph R Minter; Bryan M Edwards
Journal:  MAbs       Date:  2009-11-11       Impact factor: 5.857

10.  Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.

Authors:  T Trarbach; M Moehler; V Heinemann; C-H Köhne; M Przyborek; C Schulz; V Sneller; G Gallant; S Kanzler
Journal:  Br J Cancer       Date:  2010-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.